Literature DB >> 32581112

A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data.

Minh-Phuong Huynh-Le1,2, Chun Chieh Fan2, Roshan Karunamuni1,2, Eleanor I Walsh3, Emma L Turner3, J Athene Lane3,4, Richard M Martin3,4,5, David E Neal6,7,8, Jenny L Donovan9, Freddie C Hamdy6,10, J Kellogg Parsons11, Rosalind A Eeles12,13, Douglas F Easton14, Zsofia Kote-Jarai12, Ali Amin Al Olama14,15, Sara Benlloch Garcia14, Kenneth Muir16,17, Henrik Grönberg18, Fredrik Wiklund18, Markus Aly18,19,20, Johanna Schleutker21,22, Csilla Sipeky21, Teuvo Lj Tammela23,24, Børge Grønne Nordestgaard25,26, Timothy J Key27, Ruth C Travis27, Paul D P Pharoah28, Nora Pashayan28,29, Kay-Tee Khaw30, Stephen N Thibodeau31, Shannon K McDonnell32, Daniel J Schaid32, Christiane Maier33, Walther Vogel34, Manuel Luedeke33, Kathleen Herkommer35, Adam S Kibel36, Cezary Cybulski37, Dominika Wokolorczyk37, Wojciech Kluzniak37, Lisa A Cannon-Albright38,39, Hermann Brenner40,41,42, Ben Schöttker40,43, Bernd Holleczek40,44, Jong Y Park45, Thomas A Sellers45, Hui-Yi Lin46, Chavdar Kroumov Slavov47, Radka P Kaneva48, Vanio I Mitev48, Jyotsna Batra49,50, Judith A Clements50,51, Amanda B Spurdle, Manuel R Teixeira52,53, Paula Paulo52,54, Sofia Maia52,54, Hardev Pandha55, Agnieszka Michael55, Ian G Mills6, Ole A Andreassen56, Anders M Dale2,57, Tyler M Seibert.   

Abstract

BACKGROUND: A polygenic hazard score (PHS), the weighted sum of 54 SNP genotypes, was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we assess the potential impact of PHS-informed screening.
METHODS: United Kingdom population incidence data (Cancer Research United Kingdom) and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer were combined to estimate age-specific clinically significant prostate cancer incidence (Gleason score ≥7, stage T3-T4, PSA ≥10, or nodal/distant metastases). Using HRs estimated from the ProtecT prostate cancer trial, age-specific incidence rates were calculated for various PHS risk percentiles. Risk-equivalent age, when someone with a given PHS percentile has prostate cancer risk equivalent to an average 50-year-old man (50-year-standard risk), was derived from PHS and incidence data. Positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was calculated using PHS-adjusted age groups.
RESULTS: The expected age at diagnosis of clinically significant prostate cancer differs by 19 years between the 1st and 99th PHS percentiles: men with PHS in the 1st and 99th percentiles reach the 50-year-standard risk level at ages 60 and 41, respectively. PPV of PSA was higher for men with higher PHS-adjusted age.
CONCLUSIONS: PHS provides individualized estimates of risk-equivalent age for clinically significant prostate cancer. Screening initiation could be adjusted by a man's PHS. IMPACT: Personalized genetic risk assessments could inform prostate cancer screening decisions. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2020        PMID： 32581112      PMCID： PMC7483627          DOI： 10.1158/1055-9965.EPI-19-1527

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.254


  34 in total

1.  Computing the Cox model for case cohort designs.

Authors:  T M Therneau; H Li
Journal:  Lifetime Data Anal       Date:  1999-06       Impact factor: 1.588

2.  Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Parker; S Gillessen; A Heidenreich; A Horwich
Journal:  Ann Oncol       Date:  2015-07-22       Impact factor: 32.976

Review 3.  The personal and clinical utility of polygenic risk scores.

Authors:  Ali Torkamani; Nathan E Wineinger; Eric J Topol
Journal:  Nat Rev Genet       Date:  2018-09       Impact factor: 53.242

4.  Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.

Authors:  Olivier Rouvière; Philippe Puech; Raphaële Renard-Penna; Michel Claudon; Catherine Roy; Florence Mège-Lechevallier; Myriam Decaussin-Petrucci; Marine Dubreuil-Chambardel; Laurent Magaud; Laurent Remontet; Alain Ruffion; Marc Colombel; Sébastien Crouzet; Anne-Marie Schott; Laurent Lemaitre; Muriel Rabilloud; Nicolas Grenier
Journal:  Lancet Oncol       Date:  2018-11-21       Impact factor: 41.316

Review 5.  American Cancer Society guideline for the early detection of prostate cancer: update 2010.

Authors:  Andrew M D Wolf; Richard C Wender; Ruth B Etzioni; Ian M Thompson; Anthony V D'Amico; Robert J Volk; Durado D Brooks; Chiranjeev Dash; Idris Guessous; Kimberly Andrews; Carol DeSantis; Robert A Smith
Journal:  CA Cancer J Clin       Date:  2010-03-03       Impact factor: 508.702

6.  Association Between Older Age and Increasing Gleason Score.

Authors:  Vinayak Muralidhar; David R Ziehr; Brandon A Mahal; Yu-Wei Chen; Michelle D Nezolosky; Vidya B Viswanathan; Toni K Choueiri; Christopher J Sweeney; Quoc-Dien Trinh; Paul L Nguyen
Journal:  Clin Genitourin Cancer       Date:  2015-06-06       Impact factor: 2.872

7.  Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.

Authors:  Haitao Chen; Xu Liu; Charles B Brendler; Donna P Ankerst; Robin J Leach; Phyllis J Goodman; M Scott Lucia; Catherine M Tangen; Li Wang; Fang-Chi Hsu; Jielin Sun; A Karim Kader; William B Isaacs; Brian T Helfand; S Lilly Zheng; Ian M Thompson; Elizabeth A Platz; Jianfeng Xu
Journal:  Prostate       Date:  2016-05-16       Impact factor: 4.104

Review 8.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.

Authors:  J Ferlay; M Colombet; I Soerjomataram; T Dyba; G Randi; M Bettio; A Gavin; O Visser; F Bray
Journal:  Eur J Cancer       Date:  2018-08-09       Impact factor: 9.162

9.  Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Authors:  Tyler M Seibert; Chun Chieh Fan; Yunpeng Wang; Verena Zuber; Roshan Karunamuni; J Kellogg Parsons; Rosalind A Eeles; Douglas F Easton; ZSofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch Garcia; Kenneth Muir; Henrik Grönberg; Fredrik Wiklund; Markus Aly; Johanna Schleutker; Csilla Sipeky; Teuvo Lj Tammela; Børge G Nordestgaard; Sune F Nielsen; Maren Weischer; Rasmus Bisbjerg; M Andreas Røder; Peter Iversen; Tim J Key; Ruth C Travis; David E Neal; Jenny L Donovan; Freddie C Hamdy; Paul Pharoah; Nora Pashayan; Kay-Tee Khaw; Christiane Maier; Walther Vogel; Manuel Luedeke; Kathleen Herkommer; Adam S Kibel; Cezary Cybulski; Dominika Wokolorczyk; Wojciech Kluzniak; Lisa Cannon-Albright; Hermann Brenner; Katarina Cuk; Kai-Uwe Saum; Jong Y Park; Thomas A Sellers; Chavdar Slavov; Radka Kaneva; Vanio Mitev; Jyotsna Batra; Judith A Clements; Amanda Spurdle; Manuel R Teixeira; Paula Paulo; Sofia Maia; Hardev Pandha; Agnieszka Michael; Andrzej Kierzek; David S Karow; Ian G Mills; Ole A Andreassen; Anders M Dale
Journal:  BMJ       Date:  2018-01-10

10.  MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-03-18       Impact factor: 176.079
View more
  8 in total

1.  Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.

Authors:  Minh-Phuong Huynh-Le; Roshan Karunamuni; Chun Chieh Fan; Lui Asona; Wesley K Thompson; Maria Elena Martinez; Rosalind A Eeles; Zsofia Kote-Jarai; Kenneth R Muir; Artitaya Lophatananon; Johanna Schleutker; Nora Pashayan; Jyotsna Batra; Henrik Grönberg; David E Neal; Børge G Nordestgaard; Catherine M Tangen; Robert J MacInnis; Alicja Wolk; Demetrius Albanes; Christopher A Haiman; Ruth C Travis; William J Blot; Janet L Stanford; Lorelei A Mucci; Catharine M L West; Sune F Nielsen; Adam S Kibel; Olivier Cussenot; Sonja I Berndt; Stella Koutros; Karina Dalsgaard Sørensen; Cezary Cybulski; Eli Marie Grindedal; Florence Menegaux; Jong Y Park; Sue A Ingles; Christiane Maier; Robert J Hamilton; Barry S Rosenstein; Yong-Jie Lu; Stephen Watya; Ana Vega; Manolis Kogevinas; Fredrik Wiklund; Kathryn L Penney; Chad D Huff; Manuel R Teixeira; Luc Multigner; Robin J Leach; Hermann Brenner; Esther M John; Radka Kaneva; Christopher J Logothetis; Susan L Neuhausen; Kim De Ruyck; Piet Ost; Azad Razack; Lisa F Newcomb; Jay H Fowke; Marija Gamulin; Aswin Abraham; Frank Claessens; Jose Esteban Castelao; Paul A Townsend; Dana C Crawford; Gyorgy Petrovics; Ron H N van Schaik; Marie-Élise Parent; Jennifer J Hu; Wei Zheng; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-02-12       Impact factor: 5.455

2.  African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.

Authors:  Roshan A Karunamuni; Minh-Phuong Huynh-Le; Chun C Fan; Wesley Thompson; Rosalind A Eeles; Zsofia Kote-Jarai; Kenneth Muir; Artitaya Lophatananon; Catherine M Tangen; Phyllis J Goodman; Ian M Thompson; William J Blot; Wei Zheng; Adam S Kibel; Bettina F Drake; Olivier Cussenot; Géraldine Cancel-Tassin; Florence Menegaux; Thérèse Truong; Jong Y Park; Hui-Yi Lin; Jeannette T Bensen; Elizabeth T H Fontham; James L Mohler; Jack A Taylor; Luc Multigner; Pascal Blanchet; Laurent Brureau; Marc Romana; Robin J Leach; Esther M John; Jay Fowke; William S Bush; Melinda Aldrich; Dana C Crawford; Shiv Srivastava; Jennifer C Cullen; Gyorgy Petrovics; Marie-Élise Parent; Jennifer J Hu; Maureen Sanderson; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert
Journal:  Int J Cancer       Date:  2020-09-24       Impact factor: 7.396

Review 3.  Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management.

Authors:  David K Doan; Keith T Schmidt; Cindy H Chau; William D Figg
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

4.  A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.

Authors:  Victoria Wang; Milan S Geybels; Kristina M Jordahl; Travis Gerke; Anis Hamid; Kathryn L Penney; Sarah C Markt; Matthew Freedman; Mark Pomerantz; Gwo-Shu M Lee; Huma Rana; Daniela Börnigen; Timothy R Rebbeck; Curtis Huttenhower; Ros A Eeles; Janet L Stanford; Practical Consortium; Sonja I Berndt; Frank Claessens; Karina D Sørensen; Jong Y Park; Ana Vega; Nawaid Usmani; Lorelei Mucci; Christopher J Sweeney
Journal:  Prostate       Date:  2021-05-06       Impact factor: 4.012

5.  Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.

Authors:  Minh-Phuong Huynh-Le; Chun Chieh Fan; Roshan Karunamuni; Wesley K Thompson; Maria Elena Martinez; Rosalind A Eeles; Zsofia Kote-Jarai; Kenneth Muir; Johanna Schleutker; Nora Pashayan; Jyotsna Batra; Henrik Grönberg; David E Neal; Jenny L Donovan; Freddie C Hamdy; Richard M Martin; Sune F Nielsen; Børge G Nordestgaard; Fredrik Wiklund; Catherine M Tangen; Graham G Giles; Alicja Wolk; Demetrius Albanes; Ruth C Travis; William J Blot; Wei Zheng; Maureen Sanderson; Janet L Stanford; Lorelei A Mucci; Catharine M L West; Adam S Kibel; Olivier Cussenot; Sonja I Berndt; Stella Koutros; Karina Dalsgaard Sørensen; Cezary Cybulski; Eli Marie Grindedal; Florence Menegaux; Kay-Tee Khaw; Jong Y Park; Sue A Ingles; Christiane Maier; Robert J Hamilton; Stephen N Thibodeau; Barry S Rosenstein; Yong-Jie Lu; Stephen Watya; Ana Vega; Manolis Kogevinas; Kathryn L Penney; Chad Huff; Manuel R Teixeira; Luc Multigner; Robin J Leach; Lisa Cannon-Albright; Hermann Brenner; Esther M John; Radka Kaneva; Christopher J Logothetis; Susan L Neuhausen; Kim De Ruyck; Hardev Pandha; Azad Razack; Lisa F Newcomb; Jay H Fowke; Marija Gamulin; Nawaid Usmani; Frank Claessens; Manuela Gago-Dominguez; Paul A Townsend; William S Bush; Monique J Roobol; Marie-Élise Parent; Jennifer J Hu; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert
Journal:  Nat Commun       Date:  2021-02-23       Impact factor: 14.919

Review 6.  The Genetic Complexity of Prostate Cancer.

Authors:  Eva Compérat; Gabriel Wasinger; André Oszwald; Renate Kain; Geraldine Cancel-Tassin; Olivier Cussenot
Journal:  Genes (Basel)       Date:  2020-11-25       Impact factor: 4.096

Review 7.  Recent Insights on Genetic Testing in Primary Prostate Cancer.

Authors:  Mona Kafka; Cristian Surcel; Isabel Heidegger
Journal:  Mol Diagn Ther       Date:  2021-06-12       Impact factor: 4.074

8.  Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men.

Authors:  Minh-Phuong Huynh-Le; Roshan Karunamuni; Chun Chieh Fan; Wesley K Thompson; Kenneth Muir; Artitaya Lophatananon; Karen Tye; Alicja Wolk; Niclas Håkansson; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-03-15       Impact factor: 5.554
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.